Nanoparticles for drug delivery in Parkinson's disease

被引：30

作者：

Baskin, Jonathan ^{[1
]}

Jeon, June Evelyn ^{[1
]}

Lewis, Simon J. G. ^{[1
]}

机构：

[1] Univ Sydney, Parkinsons Dis Res Clin, Brain & Mind Ctr, Camperdown, NSW, Australia

来源：

JOURNAL OF NEUROLOGY | 2021年 / 268卷 / 05期

基金：

英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;

关键词：

Nanoparticles; Parkinson’ s disease; Blood– brain barrier; Targeted delivery; Polymeric nanoparticles; Lipid-based nanoparticles; Inorganic nanoparticles; NANOSTRUCTURED LIPID CARRIERS; BLOOD-BRAIN-BARRIER; LOADED CHITOSAN NANOPARTICLES; PEG-PLGA NANOPARTICLES; ALPHA-SYNUCLEIN; GENE-THERAPY; LACTOFERRIN RECEPTORS; INTRANASAL DELIVERY; GOLD NANOPARTICLES; RAT MODEL;

D O I：

10.1007/s00415-020-10291-x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Although effective symptomatic treatments for Parkinson's disease (PD) have been available for some time, efficient and well-controlled drug delivery to the brain has proven to be challenging. The emergence of nanotechnology has created new opportunities not only for improving the pharmacokinetics of conventional therapies but also for developing novel treatment approaches and disease modifying therapies. Several exciting strategies including drug carrier nanoparticles targeting specific intracellular pathways and structural reconformation of tangled proteins as well as introducing reprogramming genes have already shown promise and are likely to deliver more tailored approaches to the treatment of PD in the future. This paper reviews the role of nanoparticles in PD including a discussion of both their composition and functional capacity as well as their potential to deliver better therapeutic agents.

引用

页码：1981 / 1994

页数：14

共 123 条

[1] The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease [J].